BRIEF-Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers

Reuters
Jan 21
BRIEF-Actuate <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers

Jan 21 (Reuters) - Actuate Therapeutics Inc ACTU.O:

  • ACTUATE THERAPEUTICS ANNOUNCES PLANS TO EXPAND CLINICAL PIPELINE, ADVANCING ELRAGLUSIB TABLET INTO A PHASE 1/2 CLINICAL PROGRAM IN REFRACTORY CANCERS

  • ACTUATE THERAPEUTICS INC: INITIATION OF PHASE 1 PORTION OF TRIAL PLANNED IN 2H 2026

Source text: ID:nGNXbYcDk0

Further company coverage: ACTU.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10